Stock Analysis

3 Stocks Estimated To Be Undervalued By Up To 48.8%

TSE:4974
Source: Shutterstock

As global markets experience a rebound, driven by cooling inflation and strong earnings in the U.S., investors are increasingly focused on value stocks, which have recently outperformed growth shares. In this environment, identifying undervalued stocks can be a strategic approach to leverage market conditions where sectors like financials and energy show robust performance.

Top 10 Undervalued Stocks Based On Cash Flows

NameCurrent PriceFair Value (Est)Discount (Est)
Livero (TSE:9245)¥1558.00¥3105.3049.8%
Alltop Technology (TPEX:3526)NT$264.50NT$526.9649.8%
Strike CompanyLimited (TSE:6196)¥3595.00¥7189.6450%
Fevertree Drinks (AIM:FEVR)£6.575£13.1249.9%
Solum (KOSE:A248070)₩18700.00₩37346.3849.9%
North Electro-OpticLtd (SHSE:600184)CN¥10.81CN¥21.5749.9%
Vestas Wind Systems (CPSE:VWS)DKK92.60DKK184.7549.9%
ASMPT (SEHK:522)HK$75.15HK$150.0549.9%
St. James's Place (LSE:STJ)£9.315£18.6049.9%
Condor Energies (TSX:CDR)CA$1.82CA$3.6349.8%

Click here to see the full list of 873 stocks from our Undervalued Stocks Based On Cash Flows screener.

We'll examine a selection from our screener results.

Best Pacific International Holdings (SEHK:2111)

Overview: Best Pacific International Holdings Limited, along with its subsidiaries, is engaged in the manufacturing, trading, and selling of elastic fabric, elastic webbing, and lace with a market capitalization of HK$3.07 billion.

Operations: The company's revenue segments include HK$915.53 million from the manufacturing and trading of elastic webbing and HK$3.76 billion from elastic fabric and lace.

Estimated Discount To Fair Value: 46.5%

Best Pacific International Holdings is trading at HK$2.96, significantly below its estimated fair value of HK$5.54, indicating it may be undervalued based on cash flows. Despite a history of unstable dividends, the company shows strong earnings growth potential with forecasts exceeding 21% annually over the next three years. Although revenue growth is slower than 20%, it surpasses the Hong Kong market average, and recent earnings surged by 80.3%, highlighting robust financial health amidst undervaluation concerns.

SEHK:2111 Discounted Cash Flow as at Jan 2025
SEHK:2111 Discounted Cash Flow as at Jan 2025

Avant Group (TSE:3836)

Overview: Avant Group Corporation, with a market cap of ¥69.88 billion, operates through its subsidiaries to offer accounting, business intelligence, and outsourcing services.

Operations: The company's revenue segments include the Group Governance Business with ¥7.88 billion, Management Solutions Business at ¥8.96 billion, and Digital Transformation Business totaling ¥9.16 billion.

Estimated Discount To Fair Value: 48.8%

Avant Group is trading at ¥1926, considerably below its estimated fair value of ¥3763.65, suggesting potential undervaluation based on cash flows. While revenue growth is projected at 15.8% annually—slower than 20%—it outpaces the Japanese market average. Earnings are expected to grow 18.1% per year, exceeding the market's forecasted growth rate of 8%. Despite recent share price volatility, Avant Group's strong return on equity and completed buyback program underscore its financial resilience.

TSE:3836 Discounted Cash Flow as at Jan 2025
TSE:3836 Discounted Cash Flow as at Jan 2025

Takara Bio (TSE:4974)

Overview: Takara Bio Inc., with a market cap of ¥123.55 billion, operates in the bioindustry, contract development and manufacturing organization (CDMO), and gene therapy sectors across Japan, China, the rest of Asia, the United States, Europe, and internationally.

Operations: The company's revenue segments include ¥44.15 billion from its Drug Discovery Company division.

Estimated Discount To Fair Value: 40.6%

Takara Bio, trading at ¥1017, is significantly undervalued with a fair value estimate of ¥1711.93. Its earnings are forecast to grow 26% annually over the next three years, surpassing the Japanese market's growth rate of 8%. Despite recent profit margin declines from 13.2% to 2.1%, Takara Bio's revenue is expected to increase by 5.3% per year, outpacing the market average of 4.3%, highlighting potential for recovery and growth based on cash flows.

TSE:4974 Discounted Cash Flow as at Jan 2025
TSE:4974 Discounted Cash Flow as at Jan 2025

Seize The Opportunity

  • Take a closer look at our Undervalued Stocks Based On Cash Flows list of 873 companies by clicking here.
  • Hold shares in these firms? Setup your portfolio in Simply Wall St to seamlessly track your investments and receive personalized updates on your portfolio's performance.
  • Unlock the power of informed investing with Simply Wall St, your free guide to navigating stock markets worldwide.

Curious About Other Options?

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Valuation is complex, but we're here to simplify it.

Discover if Takara Bio might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

About TSE:4974

Takara Bio

Engages in bioindustry, contract development and manufacturing organization (CDMO), and gene therapy businesses in Japan, China, rest of Asia, the United States, Europe, and internationally.

Flawless balance sheet with reasonable growth potential.